Our Pricing

Understanding Wegovy BMI Requirements for UK Patients

Wegovy BMI requirements in the UK follow strict clinical eligibility criteria established by the MHRA and NICE guidelines. As a UK-registered pharmacy with thousands of weight loss consultations completed, we explain exactly who qualifies for Wegovy prescription based on body mass index and associated health conditions, ensuring you understand the criteria before starting your clinical assessment.

What Are the Official Wegovy BMI Requirements in the UK?

The Wegovy BMI requirements stipulate that adults qualify for prescription with a body mass index of 30 kg/m² or greater, classified as obese according to MHRA licensing criteria [1]. Patients with a BMI of 27 kg/m² or above may also qualify if they have at least one weight-related comorbidity such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease [2].

These eligibility thresholds align with NICE guidance for GLP-1 receptor agonist prescribing in weight management programmes across the UK. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every clinical assessment verifies BMI calculation and comorbidity status before approval. The criteria exist because semaglutide 2.4mg has demonstrated significant efficacy in clinical populations meeting these specific parameters, with the STEP trials enrolling participants within these exact BMI ranges [3].

Wegovy BMI Requirements for Patients with Health Conditions

For patients with weight-related health conditions, the Wegovy BMI requirements threshold lowers to 27 kg/m². This recognises that individuals with comorbidities face elevated health risks even at lower obesity classifications. Qualifying conditions include prediabetes or type 2 diabetes mellitus, hypertension requiring treatment, dyslipidaemia, obstructive sleep apnoea, and established cardiovascular disease [4].

During your online consultation at Cured Pharmacy, our UK-registered prescribers assess your full medical history to determine eligibility. If you have a BMI between 27-29.9 kg/m², you must provide evidence of at least one qualifying comorbidity. This dual-criteria approach ensures Wegovy prescription aligns with clinical best practice and regulatory standards set by the MHRA for safe, effective weight management.

Common Weight-Related Comorbidities That Affect Eligibility

Type 2 diabetes represents the most common qualifying condition, with semaglutide demonstrating dual benefits for glycaemic control and weight reduction in the STEP 2 trial [5]. Hypertension requiring pharmacological treatment also qualifies patients at the lower BMI threshold, as does diagnosed obstructive sleep apnoea. Cardiovascular disease history, including previous myocardial infarction or stroke, meets eligibility criteria due to the established link between obesity and cardiovascular risk. Our clinical team verifies these conditions through your medical history and may request GP confirmation for certain diagnoses before approving your Wegovy prescription.

How to Calculate Your BMI for Wegovy BMI Requirements

Body mass index calculation follows the standard formula: weight in kilograms divided by height in metres squared (kg/m²). For accurate Wegovy BMI requirements assessment, measure your weight without shoes in the morning before eating, and measure height without footwear against a flat wall. A patient weighing 95kg with a height of 1.75m would calculate: 95 ÷ (1.75 × 1.75) = 31.0 kg/m², meeting the standard eligibility threshold.

Our online consultation platform calculates your BMI automatically when you enter your height and weight, eliminating manual calculation errors. Remember that BMI represents one component of eligibility assessment—our prescribers also evaluate your weight loss history, previous treatment attempts, contraindications, and overall suitability for semaglutide therapy. Patients with BMI just below the threshold may benefit from lifestyle intervention programmes before reconsidering pharmacological treatment.

BMI Limitations and Clinical Judgement

Whilst BMI provides a standardised screening tool, it has recognised limitations for individuals with high muscle mass or certain ethnic backgrounds. NICE acknowledges that lower BMI thresholds may apply for patients of South Asian, Chinese, or Black African descent due to different body composition patterns and diabetes risk profiles. Our prescribers exercise clinical judgement when BMI falls near threshold boundaries, considering waist circumference, body composition, and ethnicity-specific risk factors. This nuanced approach ensures Wegovy prescription decisions reflect individual patient circumstances rather than rigid numerical cutoffs alone.

Wegovy BMI Requirements Compared to Other Weight Loss Medications

The Wegovy BMI requirements mirror those for other GLP-1 receptor agonists like Saxenda, which requires identical BMI thresholds of ≥30 kg/m² or ≥27 kg/m² with comorbidities. Mounjaro (tirzepatide) follows the same eligibility criteria in the UK, though it combines GLP-1 and GIP receptor agonism for potentially enhanced efficacy [6]. Orlistat, a lipase inhibitor, has slightly broader eligibility with a BMI threshold of ≥28 kg/m² or ≥25 kg/m² with risk factors, making it accessible to patients who fall just below GLP-1 agonist criteria.

At Cured Pharmacy, we stock the full range of licensed weight loss treatments, allowing our prescribers to recommend the most appropriate option based on your BMI, medical history, and treatment goals. Wegovy costs from £69.00 with transparent pricing shown before consultation, and all treatments require the same rigorous clinical assessment by our UK-registered prescribers. The choice between medications depends on individual response, injection preference versus oral formulation, and specific contraindication profiles rather than BMI eligibility alone.

What Happens If You Don't Meet Wegovy BMI Requirements?

Patients who fall below the Wegovy BMI requirements should focus on evidence-based lifestyle interventions as first-line treatment. NICE recommends structured weight management programmes combining dietary modification, increased physical activity, and behavioural support before considering pharmacological options. Our clinical team can advise on NHS-approved programmes and provide guidance on achieving the 5-10% weight loss target that significantly reduces cardiovascular risk even without medication [7].

If your BMI sits just below the threshold—for example, 26-26.9 kg/m² without comorbidities—reassessment after three to six months of lifestyle intervention may demonstrate eligibility if initial efforts prove insufficient. Alternative medications like Orlistat have lower BMI requirements and may suit patients who don't yet qualify for GLP-1 agonists. Our prescribers take a patient-centred approach, discussing all available options during your consultation and creating a realistic pathway to eligibility if Wegovy represents the optimal long-term treatment for your circumstances.

Alternative Treatments for Lower BMI Patients

Orlistat remains the primary pharmacological option for patients with BMI 28-29.9 kg/m² without qualifying comorbidities, working through fat malabsorption rather than appetite regulation. Mysimba (naltrexone/bupropion combination) offers another alternative for patients seeking prescription weight loss support, though it requires BMI ≥30 kg/m² or ≥27 kg/m² with complications. Our prescribers assess your complete clinical picture to recommend the most suitable treatment, ensuring you receive effective support regardless of whether you meet Wegovy BMI requirements initially. All prescription treatments require ongoing monitoring and lifestyle modification for optimal results.

Starting Wegovy After Meeting BMI Requirements at Cured Pharmacy

Once you meet the Wegovy BMI requirements, our streamlined process begins with a free online consultation taking under three minutes to complete. You'll provide your height, weight, medical history, current medications, and details of any weight-related health conditions. Our UK-registered prescribers review your assessment within hours, verifying BMI calculation and eligibility criteria before approving your prescription.

Wegovy costs from £69.00 at Cured Pharmacy—the cheapest UK price with transparent pricing shown upfront. New patients Save £20 using code Weightlossnew on their first order. We dispense genuine UK-licensed Wegovy in discreet packaging with next-day delivery available. Your treatment includes ongoing prescriber support, with regular follow-up assessments to monitor progress and adjust dosing according to the licensed titration schedule. Subject to prescriber approval, eligible patients can start their weight loss journey with clinical-grade semaglutide delivered directly to their door, supported by our GPhC-registered team throughout treatment.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen - Summary of Product Characteristics. GOV.UK. [accessed 15 August 2026]
2. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
4. Garvey, W. T., Mechanick, J. I., Brett, E. M., et al. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice, 22(Suppl 3), 1-203. [accessed 15 August 2026]
5. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
7. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management [CG189]. NICE. [accessed 15 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.